Clinical Trial Update: AZA+Lus VS AZA Monotherapy in HR-MDS [Phase 3]

View source ↗

Summary

Phase 3 trial comparing azacitidine plus Lus versus azacitidine monotherapy in higher-risk myelodysplastic syndrome; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Lus

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Higher-risk Myelodysplastic Syndrome | Phase 3 | Status: NOT_YET_RECRUITING